Home › Pharmaceuticals
Pharmaceuticals Market Research Reports & Consulting
Market Reports
| Title | Published | Price | TOC Available |
|---|---|---|---|
Bioprocess Validation Market by Test Type (Extractables and Leachables, Integrity Testing, Microbiology Testing), Process Component (Filter Element, Bioreactors), End-User (CDMO, Biotechnology & Pharmaceutical Companies) - Global Forecast to 2024The Bioprocess Validation Market is expected to grow from USD 180 million in 2019 to USD 360 million by 2024, at a CAGR of 14.6% during the forecast period. The prominent players operating in the bioprocess validation market are Merck KGaA (Germany), Sartorius Stedim Biotech (Sartorius AG) (France), Pall Corporation (US), SGS S.A. (Switzerland), Eurofins Scientific (Luxembourg), Cobetter Filtration Equipment Co., Ltd. (China), Toxikon Corporation (US), DOC S.r.l. (Italy), MEISSNER FILTRATION PRODUCTS, INC. (US), and Thermo Fisher Scientific (US). |
July 2019 | $ 5650 |
|
Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) - Global Forecast to 2024The Pharmaceutical Contract Development and Manufacturing Market is expected to grow from USD 90.0 billion in 2019 to USD 126.6 billion by 2024, at a CAGR of 7.1% during the forecast period. The prominent players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany). |
July 2019 | $ 5650 |
|
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohyrates, Petrochemicals) inorganic chemicals), Functionality (Fillers, Diluents, Coatings, Disintegrants), Formulation (Tablet, Capsule, Topical, Parenteral) - Global Forecast to 2025The pharmaceutical excipients market is projected to reach USD 9.7 billion by 2025 from USD 6.9 billion in 2019, at a CAGR of 5.8%. Factors such as the growing pharmaceuticals industry coupled with advancements in functional excipients, rising adoption of orphan drugs, and increasing uptake of biopharmaceuticals, are driving the market for pharmaceutical excipients. The emergence of multifunctional excipients, shifting the focus of pharmaceutical manufacturing to emerging markets, and the growing Biosimilars industry also present significant growth opportunities for market players in the pharmaceutical excipients market. DuPont de Nemours, Inc. (US) and Roquette Feres (France) dominated the global pharmaceutical excipients market in 2018. The prominent players in the global pharmaceutical excipients market are Ashland Global Holdings, Inc. (US), BASF SE (Germany), Evonik Industries AG (Germany), Associated British Foods plc (UK), Archer Daniels Midland Company (US), Lubrizol Corporation(US), and Croda International (UK). Other players in this market are Innophos Holdings (US), Kerry Group plc (Ireland), WACKER Chemie AG (Germany), Colorcon, Inc. (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France). |
June 2019 | $ 5650 |
|
Healthcare Distribution Market by Type (Pharmaceutical (Brand-name, Generic, OTC, Vitamins), Medical Device, Biopharmaceutical (Vaccines, Monoclonal Antibodies)), End User (Retail Pharmacies, Hospital Pharmacies) - Global Forecasts to 2024The healthcare distribution market is projected to reach USD 1,048.4 billion by 2024 from USD 765.4 billion in 2019, at a CAGR of 6.5%. The prominent players operating in the healthcare distribution market are McKesson Corporation (US), AmerisourceBergen Corporation (US), Cardinal Health, Inc. (US), Owens & Minor, Inc. (US), Morris and Dickson Co., LLC (US), KeySource Medical, Inc. (US), Rochester Drug Cooperative, Inc. (US), Henry Schein Inc. (US), Smith Drug Company (US), FFF Enterprises (US), Patterson Companies Inc. (US), Mutual Drug (US), Shanghai Pharmaceutical Group Co., Ltd. (China), Medline Industries (US), PHOENIX Group (Germany), and CuraScript SD (US). |
June 2019 | $ 5650 |
|
Inspection Machine Market by Product (Vision Inspection, Checkweigher, Metal Detector, Software) Type (Automatic, Manual), Packaging (Ampoules, Vials, Blisters, Bottles), End User (Pharmaceutical, Medical Devices, Food) - Global Forecast to 2024The global inspection machines market is projected to reach USD 774 million by 2024 from USD 592 million in 2019, at a CAGR of 5.5%. Regulatory mandates in the healthcare industry to maintain compliance with Good Manufacturing Practices, increasing number of inspection checkpoints in production lines, growing number of product recalls, rising penetration of automated inspection systems in the pharmaceutical & biotechnology industries, and technological evolution in inspection systems are the major factors driving the growth of this market. The prominent players operating in the inspection machines market are Robert Bosch GmbH (Germany), METTLER TOLEDO International Inc. (US), Brevetti C.E.A SPA (Italy), Jekson Vision Private Limited (India), Körber AG (Germany), Teledyne Technologies (US), Mitsubishi Chemical Holdings Corporation (Japan), Omron Corporation (Japan), Cognex Corporation (US), Thermo Fisher Scientific (US), Antares Vision (Italy), OPTEL Group (Canada), and ACG Worldwide (India). |
May 2019 | $ 5650 |
|
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market. |
May 2019 | $ 5650 |
|
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India). |
April 2019 | $ 5650 |
|
European Hemostats & Sealants Market by Brand (Hemopatch [Baxter], Tachosil [Takeda], Veriset [Medtronic], Avitene [C.R Bard], Sangustop [B Braun], Lyostypt [B Braun]), Country (Germany, Uk, France, Italy & Spain) - Forecast to 2024The European hemostats and sealants market is projected to reach USD 89 million by 2024 from USD 63 million in 2019, at a CAGR of 7.0%. The growth of this market is majorly driven by the launch of new products and favorable reimbursement scenario. However, the shift toward minimally invasive surgeries and adverse effect of hemostats are the major factors restraining the growth of this market. B. Braun (Germany), Medtronic (Ireland), C. R. Bard (US), Takeda (Japan), and Baxter (US). |
April 2019 | $ 5650 |
|
Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024The plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. The plasma fractionation market is largely driven by the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period. |
March 2019 | $ 5650 |
|
Latin America Pharmaceutical Excipients Market by Functionality (Fillers, Coating, Disintegrants, Binders, Lubricants, Preservatives, Emulsifying Agents, Lubricants, Glidants, Diluents), Country (Mexico, Argentina, Columbia, Peru) - Forecast to 2024The Latin America pharmaceutical excipients market is projected to reach USD 579 million by 2024 from USD 403 million in 2019, at a CAGR of 7.5%. Growth in this region is driven by the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; increasing focus of MNCs on investing in the pharmaceutical and healthcare sectors in Latin America; rapid growth in aging population & the subsequent increase in the prevalence of related diseases; and the availability of local and government funding for R&D activities. Prominent players in the Latin America pharmaceutical excipients market are DowDuPont (US), Roquette (France), Ashland (US), BASF (Germany), and Kerry Group (Ireland). |
March 2019 | $ 5650 |
|
Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. The key players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK). |
January 2019 | $ 5650 |
|
Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Cartoning, Case Packer, Wrapping Machine, Palletizing, Labeling & Serialization), Type (Tablet, Powder, Cream, Syrup, Aerosol) - Global Forecast to 2023The global pharmaceutical packaging equipment market is projected to reach USD 8.9 billion by 2023 from USD 6.2 billion in 2018, at a CAGR of 7.4%. The prominent players in the pharmaceutical packaging equipment market are Robert Bosch (Germany), IMA (Italy), Marchesini Group (Italy), Körber (Germany), MG2 (Italy), Uhlmann Group (Germany), Accutek Packaging Equipment Companies (US), Vanguard Pharmaceuticals Machinery (US), Romaco Holding (Germany), Bausch + Ströbel (Germany), OPTIMA Packaging Group (Germany), ACG Worldwide (India), Coesia (Italy), and MULTIVAC Group (Germany). |
November 2018 | $ 5650 |
|
Empty Capsules Market by Type ((Gelatin - Porcine, Bovine, Bone Meal), (HPMC, Pullulan)), Functionality (Sustained-release, Delayed-release), Application (Antibiotics, Vitamins, Antacids), End User (Pharma, Nutraceuticals, Cosmetics) - Forecast to 2023The global empty capsules market is projected to reach USD 2.79 billion by 2023 from USD 1.95 billion in 2018, at a CAGR of 7.4%. The growing adoption of capsule formulations among the growing geriatric population, growth of the pharmaceutical market along with the increasing R&D activities & clinical trials, and advancements in capsule delivery technologies are some of the major factors driving the growth of the empty capsules market. Emerging markets (due to their low manufacturing costs) are expected to present significant opportunities for market players. The prominent players in the global empty capsules market are Capsugel (US), ACG Worldwide (India), Qualicaps (Japan), Suheung Co. Ltd. (South Korea), CapsCanada Corporation (Canada), Qingdao Yiqing Medicinal Capsules Co., Ltd. (China), Shanxi Guangsheng Medicinal Capsules Co., Ltd (China), Healthcaps India Ltd. (India), Snail Pharma Industry Co. Ltd. (China), Roxlor (US), Sunil Healthcare Ltd. (India), Medi-Caps Ltd. (India), Nectar Lifesciences Ltd. (India), Natural Capsules Ltd. (India), and Bright Pharma Caps Inc. (US). |
October 2018 | $ 5650 |
|
Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) - Global Forecast to 2023The global superdisintegrants market is projected to reach USD 536.5 million by 2023 from USD 366.4 million in 2018, at a CAGR of 7.9%. Factors contributing to the growth of this market include the increasing adoption of orally disintegrating tablets, growing generics market, and the emergence of new superdisintegrants for the pharmaceutical industry. The shifting focus of pharmaceutical manufacturing to emerging markets and the growth of the overall pharmaceutical sector in these markets present significant opportunities for the superdisintegrants market growth. The prominent players in the global superdisintegrants market are Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette Freres (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US). |
August 2018 | $ 5650 |
|
Vaccines Market by Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Technology (Live, Toxoid, Recombinant), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023The overall vaccines market is expected to grow from USD 36.45 billion in 2018 to USD 50.42 billion by 2023, at a CAGR of 6.7% from 2018 to 2023. Market growth is attributed to the high prevalence of infectious diseases, growing support for vaccine R&D, investments into vaccine development, and a rising focus on immunization. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023. |
August 2018 | $ 5650 |
|
Nuclear Medicine/ Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023The nuclear medicine/ radiopharmaceuticals market is projected to reach $5.26 billion by 2023 from an estimated $3.95 billion in 2018 at a CAGR of 5.9%. The major influencing factors driving the growth of this market are the increasing incidence and prevalence of target conditions and initiatives to lessen the demand-supply gap of Mo-99. Cardinal Health (US), GE Healthcare (US), and Curium (France) are the key players in the nuclear medicine. Other players involved in this market are Bayer (Germany), Lantheus Medical Imaging (US), Advanced Accelerator Applications (France), and Jubilant Life Sciences (India). |
June 2018 | $ 5650 |
|
Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood) - Global Forecast to 2023The global oncology nutrition market is expected to reach USD 2.21 Billion by 2023 from USD 1.46 Billion in 2018, at a CAGR of 8.7%. Factors such as shifting focus from parenteral to enteral nutrition, increasing incidence of cancer, growing demand for nutritional feeding in the homecare sector, rising number of patients being treated for malnutrition, and increasing quality of clinical research on nutritional interventions are driving the market growth. The prominent players in the oncology nutrition market are Abbott Laboratories (US), Nestle S.A. (Switzerland), Danone (France), Fresenius Kabi AG (Germany), and B. Braun Melsungen AG (Germany). |
April 2018 | $ 16000 |
|
High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecasts to 2023The report segments this market based on type, type of manufacturer, type of synthesis, therapeutic application, and region. The market study covers the HPAPIs market from 2018 to 2023 and provides details of the factors influencing the market at both macro and micro levels along with competitive developments and recent trends in the market. The report provides a detailed analysis of the major drivers, opportunities, and strategies impacting the market along with the estimates and forecasts of the revenue and market share analysis. The global HPAPIs market is expected to reach USD 26.84 Billion by 2023 from USD 16.49 Billion in 2017, at a CAGR 8.7%. The base year considered for the study is 2017 and the forecast period is from 2018 to 2023. The HPAPIs market is fragmented, with the presence of several large as well as emerging players. Prominent players in the HPAPIs market include Pfizer (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva (Israel), Eli Lilly and Company (US), Merck (US), AbbVie (US), Mylan (US), and F. Hoffmann-La Roche (Switzerland). Players in this market are adopting various organic and inorganic strategies, such as agreements, collaborations, alliances, and partnerships; mergers and acquisitions; and expansions. |
April 2018 | $ 5650 |
|
Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023The global contract research organization (CRO) services market is projected to reach USD 56.34 Billion by 2023 from USD 39.13 Billion in 2018, at a CAGR of 7.6%. Market growth can be attributed to the growing R&D expenditure, increased outsourcing of R&D activities, and increasing number of clinical trials. The prominent players in the global CRO services market include IQVIA (US), LabCorp (US), PAREXEL (US), ICON plc (Ireland), PPD (US), PRA Health Sciences (US), Syneos Health (US), Charles River (US), Wuxi PharmaTech (US), Medpace Holdings (US), SGS (Switzerland), Envigo (UK), and MPI Research (US). |
February 2018 | $ 5650 |
|
Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Clostridial Diseases, Porcine Parvovirus), Type (Poultry, Companion Animal, Aquaculture, Porcine), Technology (Toxoid, Recombinant, Inactivated) - Global Forecast to 2022The veterinary vaccines market is expected to reach $8.66 Billion by 2022 from $6.08 Billion in 2016 at a CAGR of 5.9%. The base year considered for the study is 2016 and the forecast for the market size is provided for the period between 2017 and 2022. Zoetis (US), Merck Animal Health (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva (France), Phibro Animal Health (US), and Virbac (France) are key players in the veterinary vaccines market. Other notable players operating in this market include Vetoquinol (France), Hester (India), Hipra (Spain), IDT Biologika (Germany), China Animal Husbandry (China), Biogenesis Bago (Argentina), Tianjin Ringpu (China), and Jinyu Bio-technology (China). |
November 2017 | $ 5650 |
|
Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, Neurology) - Forecast to 2022The drug discovery services market is expected to reach USD 14.40 Billion by 2022 from USD 8.32 Billion in 2017, at a CAGR of 11.6%. The major factors driving the growth of this market are increasing research and development expenditure, inclination of major pharmaceutical companies towards outsourcing to avoid hurdles, and increasing demand for outsourcing of analytical testing and clinical trial services. Some of the major players operating in the drug discovery services market are Albany Molecular Research Inc. (AMRI) (US), Charles River Laboratories International (US), Evotec (Germany), GenScript (US), Covance (US), WuXi AppTec (China), Pharmaceutical Product Development, LLC (PPD) (US), Jubilant Biosys (India), GE Healthcare (US), Merck (Germany), Piramal Enterprises (India), and Advinus Therapeutics (India). |
October 2017 | $ 5650 |
|
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022The Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research. Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US). |
October 2017 | $ 5650 |
|
Peptide and Anticoagulant Drugs Market by Type (Hormonal (Insulin, Teriparatide, Calcitonin), Antibioctic (Colistin, Cycloserine), Low molecular weight heparin (Enaxaparin Sodium, Heparin Sodium), Application (Diabetes, Cancer) - India Forecast to 2022The Indian peptide drugs market is expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and is expected to register a CAGR of 15.0%. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market. The Indian anticoagulant drugs market is expected to reach USD 170.2 Million in 2022 from USD 127.8 Million in 2016 and is expected to register a CAGR of 4.9%. Factors such as incidence of coagulation disorders and government support for pharmaceutical companies are contributing to the growth of this market. Some of the major players operating in the Indian anticoagulant drugs market are Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India). |
August 2017 | $ 7150 |
|
Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022The global overactive bladder treatment market is projected to reach USD 4.19 Billion by 2022 from USD 3.63 Billion in 2017, at a CAGR of 2.9%. The key players in the global are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Allergan, Plc. (Ireland), Teva Pharmaceutical Industries Limited (Israel), Mylan N.V. (U.S.), Medtronic plc (Ireland), Endo International plc (Ireland), Sanofi (France), Hisamitsu Pharmaceutical Co., Inc. (Japan), Aurobindo Pharma Limited (India), Apotex Inc. (Canada), and Cogentix Medical, Inc. (U.S.) |
July 2017 | $ 5650 |
|
Stable Isotope Labeled Compounds Market by Type (C13, D, 018, N15 label), Application (Research, Clinical Diagnostics, Industrial), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospital) - Global Forecast to 2022The stable isotope-labeled compounds market is expected to reach USD 294.2 Million by 2022 from an estimated USD 254.6 Million in 2017, at a CAGR of 2.94%. The key players in the global stable isotope-labeled compounds market include Cambridge Isotopes Laboratories, Inc. (U.S.), Merck KGaA (Germany), URENCO (U.K.), IsoSciences, LLC (U.S.), Medical Isotopes, Inc. (U.S.), Omicron Biochemicals, Inc. (U.S.), Nordion (Canada) Inc., Trace Sciences International (U.S.), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), PerkinElmer Inc. (U.S.), and Rotem Industries Israel, Ltd. (Israel). |
July 2017 | $ 5650 |
|
Continuous Manufacturing Market By Product (Integrated system, Semi-continuous (Granulator, Coater, Blender), Control), Application (API, End Product (Solid Dosage)), End User (R&D Department (CRO), Pharmaceutical Companies, CMO) - Global Forecast to 2022The global continuous manufacturing market is expected to reach USD 650.4 Million by 2022 from USD 348.5 Million in 2017, at a CAGR of 13.3%. The major drivers for the market include the advantages of continuous manufacturing in pharmaceutical processes such as cost-effectiveness and improved efficiency of manufacturing and support from regulatory authorities for the implementation of continuous manufacturing. |
April 2017 | $ 5650 |
|
Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the immunotherapy drugs market. However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of immunotherapy drugs market. |
January 2017 | $ 5650 |
|
Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Fluoroquinolone), Mode of Delivery (Premixes, Oral Powder, Injection), Animal (Food-producing & Companion) - Global Forecast to 2021The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021 to reach USD 4.73 Billion by 2021. Factors such as increasing animal population, rising demand for animal-derived food products, increasing incidences of zoonotic diseases, implementation of regulations for preventing the spread of animal diseases, and rising demand for pet insurance and growing animal health expenditure are the major factors driving the growth of the global animal antibiotics and antimicrobials market. However, dearth of new antibiotics, growing resistance to antimicrobials and antibiotics, and replacement of routine prophylactic use of antibiotics by good husbandry and hygiene practices may hinder the growth of this market to certain extent. |
December 2016 | $ 5650 |
|
Sugar-Based Excipients Market by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), Type (Powder/Granule, Crystal, Syrup), Functionality (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global Forecast to 2021The global sugar excipients market is projected to reach USD 1,060.6 Million by 2021 from USD 860.6 Billion in 2016, at a CAGR of 4.3% from 2016 to 2021. The sugar excipients market is expected to witness significant growth in the coming years due to the increasing use of co-processed excipients, rapid growth in the generics market due to the patent expiration of many blockbuster drugs, and increasing development of orally disintegrating tablets (ODTs). |
December 2016 | $ 5650 |
|
Veterinary Surgical Instruments Market by Product (Sutures, Foreceps, Scissors, Electrosurgery Instruments, Cannulas), Animal (Canines, Felines, Large Animals), Application (Soft tissue, Sterilization, Gynecology, Orthopedic Surgery) - Forecast to 2021The global veterinary surgical instruments market is estimated to reach USD 1,029.0 Million by 2021 from USD 748.4 Million in 2016, grow at a CAGR of 6.6% during the forecast period. The increasing demand for veterinary surgical instruments is driven by the rising companion animal population coupled with the growing demand for pet insurance, the rising animal health awareness levels along with the increasing animal healthcare expenditure. |
November 2016 | $ 5650 |
|
Animal Wound Care Market by Product [Surgical (Suture, Sealant, Glue) Advanced (Film, Foam, Hydrogel, Hydrocolloid dressing) Traditional (Dressing, Bandage, Absorbent, Tape) & NPWT Device] Animal (Companion, Livestock) & End User - Global Forecast to 2021The animal wound care market is expected to witness significant growth in the coming years. The global animal wound care market is projected to reach USD 1,134.0 Million by 2021 from USD 818.8 Million in 2016, at a CAGR of 6.7% from 2016 to 2021. Factors such as growing population of companion as well as livestock animals; rising demand for pet insurance along with increasing animal healthcare expenditure; and increasing number of veterinary practitioners and their income levels in developed regions are the major drivers for the growth of the animal wound care market. |
November 2016 | $ 5650 |
|
Asia-Pacific Animal Health Market by Product (Parasiticides (Endoparasiticides, Ectoparasiticides), Antimicrobial & Antibiotic, Vaccines, Feed Additive (Vitamin, Amino Acids, Antioxidant), Growth Promoter), Animal (Livestock, Companion) - Forecast to 2021The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period to reach USD 20.25 Billion by 2021. Factors such as the rapid rise in livestock population, increasing awareness about animal health, growing demand for animal-derived food products, and rising frequency of animal disease outbreaks are the major factors driving the growth of the APAC animal health market. However, restrictions on the use of parasiticides in food-producing animals, rising storage cost of animal vaccines, and the shift towards vegetarian diets are restraining the growth of this market to a certain extent. |
October 2016 | $ 5650 |
|
Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021The global bleeding disorders treatment market is expected to reach USD 15.09 Billion by 2021 from USD 10.33 Billion in 2016 at a CAGR of 7.9% from 2016 to 2021. The major factors driving the market growth include the growing patient population base, R&D activities, and increasing focus on recombinant products by pharmaceutical companies. Emerging markets offer significant growth opportunities for the bleeding disorders treatment market. |
July 2016 | $ 5650 |
|
Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan)The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 Million by 2021, at a CAGR of 13.9% from 2016 to 2021. Over the years, the sunitinib malate market for pancreatic cancer has observed steady growth and this trend is expected to continue in the coming years. This is primarily because the market is witnessing increasing adoption of drug therapy for the treatment of pancreatic cancer. This report categorizes patients with pancreatic neuroendocrine tumors (pNET) based on three different stages, namely, localized, advanced, and distant. |
May 2016 | $ 5650 |
|
Enteral Feeding Formulas Market by Product (Polymeric, Monomeric, Disease-Specific Formulas), by Stage (Adults, Pediatrics), by Application (Oncology, Gastroenterology, Neurology), by End User (Hospitals, LTCS, Home Care) - Global Forecast to 2020The global enteral feeding formulas market is estimated to reach USD 5.95 Billion by 2020, growing at a CAGR of 7.6% during the forecast period. The enteral feeding formulas market is mainly driven by the rising incidences of chronic diseases and disorders, the rapidly increasing geriatric population, increasing healthcare expenditure, rising prevalence of preterm births, and increasing demand for homecare. |
March 2016 | $ 5650 |
|
Animal Parasiticides Market by Product (Endoparasiticides, Ectoparasiticides, Endectocides, Oral Liquids, Tablets, Injectables, Sprays, Pour-on, Spot-on, Collars, Ear Tags) by Animal (Dogs, Cats, Cattle, Pigs, Sheep and Goats, Poultry) - Global Forecast to 2020The global animal parasiticides market is estimated to grow at a CAGR of 5.7% from 2015 to 2020 to reach USD 9.7 Billion by 2020. Growing concerns of zoonotic diseases, regulations for preventing spread of animal diseases, growing companion animals’ population, rising demand for animal-derived food products, and rising animal health expenditure are key factors driving the growth of the global animal parasiticides market. However, diversity of parasite species and regulated usage of parasiticides in food-producing animals may hinder the growth of this market to certain extent. |
February 2016 | $ 5650 |
|
European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Thyroid, Cardiology), Procedures - Forecasts to 2020Over the years, the European nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The European radiopharmaceuticals market is witnessing growth owing to an increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 radioisotopes are estimated to contribute the highest to the European nuclear medicine diagnostic market in 2015, whereas Ra-223, I-131 and Y-90 ensured their leading position in the therapeutic market. The European nuclear medicine/radiopharmaceuticals market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, growing at a CAGR of 8.2% from 2015 to 2020. |
November 2015 | $ 5650 |
|
Wellness Supplements Market by Product (Dietary Supplements (Vitamin, Mineral, Protein, Herbal), Functional/Fortified Food & Beverages, Food Intolerance (Gluten-Free, Lactose-Free), Dermo-Cosmetic Skin Essentials (Anti-Acne)) - Global Forecast to 2020The global Wellness Supplements market is expected to reach USD 249.4 Billion by 2020 from USD 183.1 Billion in 2015, at a CAGR of 6.4% during the forecast period. The growth of wellness supplement is mainly driven by factors such as rising geriatric population, growing prevalence of chronic diseases, rising awareness about benefits of wellness supplements, rising healthcare costs, and shift of consumers from care to preventive. However, regulatory compliance is likely to restrain the growth of wellness supplement market to a certain extent. |
November 2015 | $ 5650 |
|
Clinical Trial Supplies Market by Products & Services (Logistics & Distribution, Manufacturing, Packaging and Labeling), Phases (Phase I, Phase II, Phase III) & Therapeutic Areas (CNS & Mental Disorders, Cardiovascular, Oncology) - Global Forecast to 2020The global clinical trial supplies market is expected to reach USD 1,274.3 Million by 2020 from USD 904.3 Million in 2015, at a CAGR of 7.1%. The global clinical trial supplies market is broadly classified into manufacturing services, packaging and labeling services, and logistics and distribution services. The logistics and distribution segment is expected to account for the largest share of the global clinical trial supplies products market in 2015. |
October 2015 | $ 5650 |
|
U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020The U.S. general anesthesia drugs market is poised to reach ~USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020. Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are key factors driving the growth of the U.S. general anesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market. |
July 2015 | $ 5650 |
|
Freeze Drying / Lyophilization Equipment Market by Scale (Lab, Pilot, & Industrial), Technology (Rotary, Manifold, & Tray - style) & by Accessories (Loading/Unloading System, Vacuum System, Clean-in-Place System, Control System) - Global Forecast to 2019Freeze drying is an efficient method for drying various unstable, heat sensitive, aqueous products in various industries. In the healthcare industry, freeze drying is mostly used in pharmaceutical and biotech manufacturing. The global freeze drying market was valued at $1,969.7 million in 2014 and is expected to reach at $2,655.9 million by 2019, at a CAGR of 6.2% during the forecast period of 2014 to 2019. This market is mainly driven by the increasing demand for lyophilization of biopharmaceutical and other high-value formulations in pharmaceutical and biotechnology industry. |
September 2014 | $ 5650 |
|
Cleanroom Technology Market by Equipment (HVAC System, HEPA Filter, Air Shower, Air Diffuser), Consumables (Apparel, Gloves, Wipes, Disinfectants), Construction (Hardwall, Softwall), & by End User (Pharmaceutical, Biotech) – Global Forecast to 2019Over the years, the demand for cleanrooms for healthcare industry has increased significantly owing to the stringent healthcare regulations, emergence of biologics, growing pharmaceutical industry, and rising application of cleanrooms in medical device industry. Further, the growing healthcare industry in the developing regions such as China and India would provide extensive growth opportunities for the cleanroom technology market. However, high cost associated with installation and use of cleanrooms would be restraining the growth of healthcare cleanrooms market during the forecast period to a certain extent. |
September 2014 | $ 5650 |
|
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen. |
December 2013 | $ 5650 |
|
North America Weight Loss /Obesity Management Market – [Meal Replacements, Slimming Centers, Nutrition & Psychological Consultancy, Treadmill, Ellipticals, Strength Training, Gastric Bypass, Intragastric Balloon System, StomaphyX] – Forecasts to 2017Obesity and weight gain have always been major concerns regarding the health and fitness of individuals; today, it has reached the level of an epidemic. Increasing obesity rate and increasing levels of awareness amongst calorie-conscious consumers in North America have opened new avenues for the weight management industry. |
July 2013 | $ 5650 |
|
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%. |
May 2013 | $ 5650 |
|
Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012 – 2017) - (Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases)Autologous cell therapies are new therapeutic intervention where it introduces or uses cells or tissues from the individual, cultured, expanded and re-introduced at the site of the disease of the donor. They are widely promoted as next pillar or advancement in medical care. Autologous Stem Cell market is currently estimated as $650 million, including products of all application areas. This market is anticipated to reach $2.2 billion by 2017, growing at a CAGR of 21%. ACT has already been successful in the treatment of prostate cancer, skin burns, cosmetic surgeries, skin substitutes, wound healing, pressure ulcers, etc. |
October 2012 | $ 5650 |
|
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug. |
December 2011 | $ 5650 |
|
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. |
November 2011 | $ 5650 |
|
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countriesLung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer. |
November 2011 | $ 5650 |
|
Global Clinical Trials Market (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)This research report categorizes the Global Clinical Trials Market on the basis of phases, indications, and study design analyzing trends in each. Each section will provide market data, market drivers, trends and opportunities, key players, and competitive outlook. This report will also provide more than 20 company profiles. |
September 2011 | $ 5650 |
|
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.
Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement
Connect With Us
Live Chat Support
Search reports
Pharmaceuticals ›
Information and Communications Technology ›
Semiconductor and Electronics ›
Medical Devices ›
Chemicals ›
Advanced Materials ›
Energy and Power ›
Food and Beverage ›
Biotechnology ›
Aerospace and Defence ›
Healthcare IT ›
Automotive and Transportation ›
Automation and Process Control ›
Agriculture Industry ›
Packaging ›
Building and Construction ›
Mining, Minerals and Metals ›
Analytical and Scientific Instrumentation ›
Engineering Equipment and Devices ›
'Connect With Us
